健康元：玛帕西沙韦胶囊（壹立康 ）获得药品注册证书

Core Viewpoint - The company, Health元, has received approval from the National Medical Products Administration for its innovative anti-influenza drug, Marpacisavir Capsules (Yilikan), which is designed for the treatment of uncomplicated influenza A and B in adolescents and adults aged 12 and above [1] Group 1 - The drug requires only a single dose for the entire treatment course [1] - It demonstrates good efficacy against both influenza A and B virus infections, with superior efficacy against influenza B compared to similar drugs [1] - The drug shows particularly strong efficacy in treating influenza in adolescents, with a lower risk of resistance and significant safety advantages [1]